U.S., March 13 -- ClinicalTrials.gov registry received information related to the study (NCT07466303) titled 'Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer' on Feb. 23.
Brief Summary: To evaluate the efficacy and safety of Serplulimab in combination with Trastuzumab Restuzumab for the neoadjuvant treatment of triple-negative breast cancer, aiming to provide evidence for optimizing the strategy of combining immunotherapy with ADC drugs in the neoadjuvant setting.
Study Start Date: March 25
Study Type: INTERVENTIONAL
Condition:
Breast Cancer
Serplulimab Combined With SHR-A1811 as Neoadjuvant Therapy for Triple-Negative Breast Cancer
Intervention:
DRUG: Serplulimab
Administered...